AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25103167 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based voluntary counselling and testing for HIV (36 months)
Number of subjects: 56683
Study 25103167 — intervention group
Group type: COMPARATOR
Intervention: Standard counselling and testing alone (control group)
Number of subjects: 56683
Study 22088938 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT (tobacco dependence treatment before CT scan)
Number of subjects: 18
Study 22088938 — intervention group
Group type: COMPARATOR
Intervention: ACT (CT scan before tobacco dependence treatment)
Number of subjects: 18
Study 19773226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow cells (BMCs)
Number of subjects: 60
Study 19773226 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BMC transfer)
Number of subjects: 60
Study 17635377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg daily
Number of subjects: 89
Study 17635377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg daily
Number of subjects: 89
Study 17635377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 15088089 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted MR imaging (DWI)
Number of subjects: 268
Study 15088089 — intervention group
Group type: COMPARATOR
Intervention: CT imaging
Number of subjects: 268
Study 15088089 — intervention group
Group type: COMPARATOR
Intervention: High-resolution MRI
Number of subjects: 268
Study 10866879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (0.5 mg/kg dose-1) IV after surgery and every 6 h for 48 h
Number of subjects: 24
Study 10866879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent volume saline) IV after surgery and every 6 h for 48 h
Number of subjects: 24
Study 10866879 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 24
Study 10866879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9348595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 28
Study 8149689 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril (200 mg) given twice daily for 10 days
Number of subjects: 12
Study 8149689 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatril (200 mg)
Number of subjects: 12
Study 8149689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2943780 — intervention group
Group type: EXPERIMENTAL
Intervention: 3F recanalization catheter (group I)
Number of subjects: 162
Study 2943780 — intervention group
Group type: EXPERIMENTAL
Intervention: 4F Grüntzig balloon catheter (group II)
Number of subjects: 162
Study 31248932 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive Parenting intervention
Number of subjects: 60
Study 31248932 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition (psychoeducation parent groups)
Number of subjects: 60
Study 28531312 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography (EMG) assessment of facial muscle activity in response to tastants
Number of subjects: 0
Study 25285987 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the left temporoparietal area combined with auditory stimulation (broadband noise at tinnitus minimum masking level + 10 dB)
Number of subjects: 10
Study 25285987 — intervention group
Group type: COMPARATOR
Intervention: Sham controlled session
Number of subjects: 10
Study 23727759 — intervention group
Group type: EXPERIMENTAL
Intervention: Whortleberry fruit hydroalcoholic extract (1 capsule = 350 mg, every 8 h for 2 months)
Number of subjects: 37
Study 23727759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 21502969 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (dutasteride 0.5 mg plus tamsulosin 0.4 mg)
Number of subjects: 2925
Study 21502969 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg
Number of subjects: 2925
Study 21502969 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg
Number of subjects: 2925
Study 19149835 — intervention group
Group type: EXPERIMENTAL
Intervention: l-cystine and l-theanine
Number of subjects: 65
Study 19149835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 16875911 — intervention group
Group type: COMPARATOR
Intervention: Pexelizumab bolus plus infusion (n = 2476)
Number of subjects: 5916
Study 16875911 — intervention group
Group type: COMPARATOR
Intervention: Pexelizumab bolus only (n = 937)
Number of subjects: 5916
Study 16875911 — intervention group
Group type: COMPARATOR
Intervention: Pexelizumab bolus plus infusion or bolus only (n = 3429)
Number of subjects: 5916
Study 12776646 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 40
Study 12776646 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 40
Study 12776646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 40
Study 12776646 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study 11055473 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary sodium intake (300 mmol/day)
Number of subjects: 42
Study 11055473 — intervention group
Group type: COMPARATOR
Intervention: Low dietary sodium intake (50 mmol/day)
Number of subjects: 42
Study 9204060 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath-5-MOP-UVA
Number of subjects: 22
Study 9204060 — intervention group
Group type: COMPARATOR
Intervention: Bath-8-MOP-UVA
Number of subjects: 22
Study 8454143 — intervention group
Group type: COMPARATOR
Intervention: 23-gauge Teflon cannula
Number of subjects: 142
Study 8454143 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-gauge winged steel needle
Number of subjects: 142
Study 3756064 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 10 micrograms min‐1
Number of subjects: 6
Study 3756064 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 0.2 mg kg‐1 min‐1
Number of subjects: 6
Study 3756064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactive intestinal peptide (VIP) 6 pmol kg‐1 min‐1
Number of subjects: 6
Study 3756064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31473512 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg choline/day for 12 weeks
Number of subjects: 26
Study 31473512 — intervention group
Group type: EXPERIMENTAL
Intervention: 930 mg choline/day for 12 weeks
Number of subjects: 26
Study 31473512 — intervention group
Group type: EXPERIMENTAL
Intervention: 2× choline diet in mice
Number of subjects: 26
Study 31473512 — intervention group
Group type: EXPERIMENTAL
Intervention: 4× choline diet in mice
Number of subjects: 26
Study 31473512 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants in CHDH
Number of subjects: 26
Study 31473512 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants in BHMT
Number of subjects: 26
Study 29712560 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous care intervention (CCI) including nutritional ketosis
Number of subjects: 349
Study 29712560 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 349
Study 28430318 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal, face-to-face traditional education
Number of subjects: 30
Study 28430318 — intervention group
Group type: COMPARATOR
Intervention: Self-directed internet-based education
Number of subjects: 30
Study 28430318 — intervention group
Group type: COMPARATOR
Intervention: No education
Number of subjects: 30
Study 25622594 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive high-load strength training
Number of subjects: 260
Study 25622594 — intervention group
Group type: COMPARATOR
Intervention: General low-load exercises
Number of subjects: 260
Study 22951087 — intervention group
Group type: EXPERIMENTAL
Intervention: PN-led care
Number of subjects: 0
Study 22951087 — intervention group
Group type: COMPARATOR
Intervention: Usual GP-led care
Number of subjects: 0
Study 21918168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine group (2 mL hyperbaric 0.5% bupivacaine plus 0.6 mL 1% lidocaine)
Number of subjects: 50
Study 21918168 — intervention group
Group type: COMPARATOR
Intervention: Control group (2 mL hyperbaric 0.5% bupivacaine plus 0.6 mL saline)
Number of subjects: 50
Study 21918168 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 21918168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine group
Number of subjects: 50
Study 21918168 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 18158291 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise training (SET) programme
Number of subjects: 40
Study 18158291 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric hyperproteic diet
Number of subjects: 40
Study 17060567 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (QD)
Number of subjects: 0
Study 17060567 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice daily (BID)
Number of subjects: 0
Study 17060567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12717126 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shocks
Number of subjects: 91
Study 12717126 — intervention group
Group type: COMPARATOR
Intervention: Monophasic shocks
Number of subjects: 91
Study 10736328 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol esters (0.8 g/d)
Number of subjects: 22
Study 10736328 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol esters (1.6 g/d)
Number of subjects: 22
Study 10736328 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol esters (2.4 g/d)
Number of subjects: 22
Study 7924852 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% indomethacin (Indoptic) eye drops
Number of subjects: 21
Study 7924852 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 unaffected children)
Number of subjects: 21
Study 3073765 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg aspirin per day
Number of subjects: 701
Study 3073765 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg aspirin per day
Number of subjects: 701
Study 31749113 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD-11101 (biosimilar of darbepoetin-alfa)
Number of subjects: 403
Study 31749113 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin-alfa
Number of subjects: 403
Study 29220619 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) group performing a progressive static WBV program after initial training.
Number of subjects: 20
Study 29220619 — intervention group
Group type: COMPARATOR
Intervention: Control group performing no further training after initial training.
Number of subjects: 20
Study 29220619 — intervention group
Group type: COMPARATOR
Intervention: Whole-body vibration (WBV) group and Control group.
Number of subjects: 20
Study 28949898 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy-enhanced individualized assent/consent procedure (separated during consent process)
Number of subjects: 64
Study 28949898 — intervention group
Group type: COMPARATOR
Intervention: Traditional assent/consent procedure (together during consent process)
Number of subjects: 64
Study 28703900 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid genetic counseling and testing (RGCT)
Number of subjects: 265
Study 28703900 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 265
Study 28703900 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counseling and testing (GCT)
Number of subjects: 265
Study 28703900 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral source
Number of subjects: 265
Study 24129239 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine
Number of subjects: 357
Study 24129239 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 357
Study 21188596 — intervention group
Group type: EXPERIMENTAL
Intervention: PG102
Number of subjects: 90
Study 21188596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 19321052 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified pigtail probes (Group B)
Number of subjects: 87
Study 19321052 — intervention group
Group type: COMPARATOR
Intervention: Traditional pigtail probes (Group A)
Number of subjects: 87
Study 17846266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral acute ventral pallidal stimulation
Number of subjects: 22
Study 17846266 — intervention group
Group type: COMPARATOR
Intervention: Bilateral acute dorsal pallidal stimulation
Number of subjects: 22
Study 15221200 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 16
Study 15221200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11440090 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS), 100 mg/kg/d for 5 days
Number of subjects: 451
Study 11440090 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (BSS)
Number of subjects: 451
Study 11440090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 9534983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid biopterin levels
Number of subjects: 130
Study 9534983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid NO concentrations
Number of subjects: 130
Study 9534983 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage activation markers, neopterin, and sTNFR‐75
Number of subjects: 130
Study 9534983 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Th1 response
Number of subjects: 130
Study 9534983 — intervention group
Group type: EXPERIMENTAL
Intervention: Local production of NO
Number of subjects: 130
Study 7587909 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotic device treatment
Number of subjects: 20
Study 7587909 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 20
Study 2312473 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (650 mg)
Number of subjects: 7
Study 2312473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 490883 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care (SC)
Number of subjects: 4
Study 490883 — intervention group
Group type: COMPARATOR
Intervention: Referred Care (RC)
Number of subjects: 4
Study 31243478 — intervention group
Group type: EXPERIMENTAL
Intervention: Imrecoxib 100 mg
Number of subjects: 24
Study 28426849 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg subcutaneous loading dose followed by 40 mg every other week)
Number of subjects: 443
Study 28426849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 28426849 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 443
Study 26196078 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated support
Number of subjects: 239
Study 26196078 — intervention group
Group type: EXPERIMENTAL
Intervention: Human support
Number of subjects: 239
Study 23391776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antihypertensive treatment targeting systolic BP <150 mm Hg
Number of subjects: 75
Study 23391776 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antihypertensive treatment targeting systolic BP <180 mm Hg
Number of subjects: 75
Study 21921208 — intervention group
Group type: EXPERIMENTAL
Intervention: LC16m8
Number of subjects: 0
Study 21921208 — intervention group
Group type: COMPARATOR
Intervention: Dryvax
Number of subjects: 0
Study 19851919 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer skill training and logistic support including a planning workshop for information diffusion
Number of subjects: 0
Study 19851919 — intervention group
Group type: EXPERIMENTAL
Intervention: Computers only
Number of subjects: 0
Study 19851919 — intervention group
Group type: COMPARATOR
Intervention: Control group (no full program)
Number of subjects: 0
Study 16500015 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLS intervention with early administration of sodium bicarbonate
Number of subjects: 874
Study 16500015 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLS intervention
Number of subjects: 874
Study 16500015 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport time
Number of subjects: 874
Study 16500015 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate administration
Number of subjects: 874
Study 15631248 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 980
Study 15631248 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 980
Study 11884105 — intervention group
Group type: EXPERIMENTAL
Intervention: Enlargement reconstruction of the flexor retinaculum with synovectomy
Number of subjects: 91
Study 11884105 — intervention group
Group type: COMPARATOR
Intervention: Conventional carpal tunnel release
Number of subjects: 91
Study 9202101 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (240 mg)
Number of subjects: 10
Study 9202101 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee with supplemental caffeine (2 mg/kg body wt)
Number of subjects: 10
Study 9202101 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 10
Study 7878506 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair (LHR) under general anesthesia (GA)
Number of subjects: 86
Study 7878506 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair (OHR) under local anesthetic (LA)
Number of subjects: 86
Study 7878506 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair (LHR)
Number of subjects: 86
Study 3285017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg daily via gastrointestinal tract for 21 days or until discharge)
Number of subjects: 71
Study 3285017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 3285017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 71
Study 29047035 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-Resolution Convolutional Neural Network (SRCNN)
Number of subjects: 89
Study 29047035 — intervention group
Group type: COMPARATOR
Intervention: Linear interpolation methods
Number of subjects: 89
Study 28619176 — intervention group
Group type: EXPERIMENTAL
Intervention: JZP-110
Number of subjects: 126
Study 28619176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 25614603 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine mouth rinse (CAF) 0.3 g/25 ml
Number of subjects: 10
Study 25614603 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin mouth rinse (MALT) 1.6 g/25 ml
Number of subjects: 10
Study 25614603 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse (PLAC)
Number of subjects: 10
Study 22633472 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg simvastatin (sim80)
Number of subjects: 31
Study 22633472 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg simvastatin and 10 mg ezetimibe (sim10eze10)
Number of subjects: 31
Study 22633472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 20680372 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical decompression of the lumbar spine without fusion
Number of subjects: 159
Study 19463387 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté 2.25 mm
Number of subjects: 411
Study 19463387 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté 38 mm
Number of subjects: 411
Study 19463387 — intervention group
Group type: COMPARATOR
Intervention: TAXUS Express
Number of subjects: 411
Study 17406757 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori treatment with omeprazole, clarithromycin, and amoxicillin for 7 days
Number of subjects: 56
Study 17406757 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori positive rate in tumor tissue
Number of subjects: 56
Study 17406757 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori presence in adjacent non-tumor gastric mucosa
Number of subjects: 56
Study 17406757 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of H. pylori prevalence in intestinal vs diffuse carcinomas
Number of subjects: 56
Study 17406757 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic gastritis and atrophic mucosa in adjacent non-tumor gastric mucosa
Number of subjects: 56
Study 12793516 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Assisted Cognitive-Behaviour Therapy (MACT)
Number of subjects: 480
Study 12793516 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 480
Study 11053707 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term heart rate variability (HRV) analysis before ventricular tachycardia (VT)
Number of subjects: 0
Study 11053707 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral analysis of HRV before VT
Number of subjects: 0
Study 11053707 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling exponent beta of the power-frequency relation before VT
Number of subjects: 0
Study 8971904 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (9 infants, group B)
Number of subjects: 30
Study 8971904 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin (10 infants, group A)
Number of subjects: 30
Study 8971904 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin (10 infants, group C)
Number of subjects: 30
Study 8971904 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 newborns who did not receive antibiotics)
Number of subjects: 30
Study 1281066 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry with thiazole orange
Number of subjects: 289
Study 1281066 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry with thiazole orange (increased concentration)
Number of subjects: 289
Study 1281066 — intervention group
Group type: COMPARATOR
Intervention: Flow cytometry, image analysis, manual counting
Number of subjects: 289
Study 6089074 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS) at 80 microseconds rectangular waves at 85 Hz
Number of subjects: 0
Study 6089074 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation at 0.5 Hz
Number of subjects: 0
Study 30739002 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) in addition to best available care
Number of subjects: 520